Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 19/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 15/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 13/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 0.78 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.78 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.78 |
| ▸ | ULK1 | O75385 | 1/20 | 0.78 |
| ▸ | STK10 | O94804 | 1/20 | 0.78 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.78 |
| ▸ | CDK1 | P06493 | 1/20 | 0.78 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.78 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.78 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.78 |
| ▸ | CDK2 | P24941 | 1/20 | 0.78 |
| ▸ | TYK2 | P29597 | 1/20 | 0.78 |
| ▸ | FLT3 | P36888 | 1/20 | 0.78 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12268525 | 0.90 | CSNK2A1 (0.82) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL13687863 | 0.90 | CSNK2A1 (0.83) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL4974026 | 0.90 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL10131496 | 0.89 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL10131410 | 0.89 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL10131655 | 0.89 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| SCHEMBL4971384 | 0.88 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| Silmitasertib SCHEMBL629082 | 0.88 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| Silmitasertib SCHEMBL29381056 | 0.88 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 | |
| Silmitasertib SCHEMBL30193004 | 0.88 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458047-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INST NAT SANTE RECH MED (FR) | 2022-08-03 | — | — | EP | disclosed |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | INSERM (INSTITUT NATION DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2022-06-21 | — | — | US | disclosed |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-12-17 | — | — | US | disclosed |
| US-20190002569-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | UNIVERSITÉ PARIS CITÉ (FR) | 2019-01-03 | — | — | US | disclosed |
| US-20170051062-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-02-23 | — | — | US | disclosed |
| WO-2015124588-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY THE NRP-1/OBR COMPLEX SIGNALING PATHWAY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| WO-2011041785-A1 | BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051062-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | NR0B1, NRP1, NR0B2 | CSNK2A1 1045/4885CSNK2A2 1183/4885CSNK2B 897/4885 |
| US-11364219-B2 | Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption | PER2, CRY1, CRY2 | CSNK2A1 5/4885CSNK2A2 4/4885CSNK2B 7/4885 |
| US-20190002569-A1 | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway | NR0B1, NRP1, NR0B2 | CSNK2A1 1045/4885CSNK2A2 1183/4885CSNK2B 897/4885 |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A1 24/4885CSNK2A2 37/4885CSNK2B 39/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A1 24/4885CSNK2A2 37/4885CSNK2B 39/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
| US-20200390740-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION | PER2, CRY1, CRY2 | CSNK2A1 5/4885CSNK2A2 4/4885CSNK2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.